Showing 1 - 10 of 227
Persistent link: https://www.econbiz.de/10003538632
Persistent link: https://www.econbiz.de/10003836342
Persistent link: https://www.econbiz.de/10010197624
Persistent link: https://www.econbiz.de/10003516196
Persistent link: https://www.econbiz.de/10009248058
Care of stroke patients costs considerably more in specialized stroke units (SU) compared to care in general medical wards (GMW) but the technology may be cost effective if it leads to significantly improved outcomes. While randomized control trials show better outcomes for stroke patients...
Persistent link: https://www.econbiz.de/10010528450
Persistent link: https://www.econbiz.de/10009786263
New drug introductions are a key to growth for pharmaceutical firms. However not all innovations are the same and they may have differential effects that vary by firm size. We use quarterly sales data on UK pharmaceuticals in a dynamic panel model to estimate the impact of product (new drugs)...
Persistent link: https://www.econbiz.de/10012903446
We uses ADHD drugs sales data from 2000-2003 and compare estimates of elasticities and merger simulations from three different demand models. Models include logit, random coefficients logit, and conditional AIDS demand model with multistage budgeting. The magnitude of cross-price elasticities is...
Persistent link: https://www.econbiz.de/10012968084
During patent litigation, pay-for-delay deals involve a payment from a patent holder of a branded drug to a generic drug manufacturer to delay entry and withdraw the patent challenge. In return for staying out of the market, the generic firm receives a payment, and/or an authorized licensed...
Persistent link: https://www.econbiz.de/10012856155